Navigation Links
Palatin Technologies to Present at 9th Annual BIO Investor Forum
Date:10/1/2010

CRANBURY, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the 9th Annual BIO Investor Forum on Wednesday, October 6, 2010 at 8:00 AM PT.  Hosted by the Biotechnology Industry Organization (BIO), the 9th Annual BIO Investor Forum will take place October 5-6 at the Palace Hotel in San Francisco, CA.  

Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin's corporate and development programs.  A live audio broadcast will be available on the "Investors" section of Palatin's website at www.palatin.com.  The live audio broadcast will be available through October 13, 2010.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Palatin Technologies to Present at Rodman & Renshaw Annual Global Investment Conference
2. Palatin Technologies, Inc. Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men
3. Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca
4. Palatin Technologies, Inc. To Raise $2.6 Million Dollars in Registered Direct Offering
5. Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
6. Palatin Technologies to Present at 8th Annual BIO Investor Forum
7. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
8. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
9. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
10. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
11. Wound Management Technologies, Inc. Furthers its Government Initiatives and Business Development within the Veterans Health Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016 Research and Markets ... Surgery Products Market 2016-2020" report to their offering. ... The global plastic surgery products market is ... the period 2016-2020. , ,The growing adoption of laser ... growth of the market. Lasers are used to treat ...
(Date:4/28/2016)... , April 28, 2016 ... , George Phillips und ... Unternehmens    ArisGlobal®, ein führender ... Sciences, gab heute bekannt, dass neue Führungskräfte ... Unternehmens gestoßen sind, die vielfältige Erfahrungen mitbringen. ...
(Date:4/28/2016)... -- Treato , the single largest ... that it has been named a Cool Vendor by ... Sciences, 2016, Stephen Davies , Michael ... life-science- oriented analytics, algorithms and smart machine technology in ... medication ingestion, and analyze unstructured information.   ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. ... of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death ... podcasted thereafter . Dr. Bernie Siegel, author of a plethora of essential ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine ... announce one of their physicians has been invited to be a featured speaker at ... Practice Review conference on April 30, 2016. , Dr. R. Scott McPherson, a ...
(Date:4/29/2016)... ... 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 ... skin cancer deaths. More than 10,000 people are expected to die of melanoma this year. ... is the one of the most commonly diagnosed cancers in young women. A recent breakthrough ...
(Date:4/29/2016)... ... 29, 2016 , ... Jvion, the market leader in clinical ... Eastside Partners, with participation from existing investor Martin Ventures. The funds will ... technology and product roadmap. , “Jvion is experiencing significant growth and ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Nike Softball ... softball camp from July 24th – 27th for girls aged 10-18. All facets of ... held at the beautiful Clark V. Whited Complex, one of the finest softball facilities ...
Breaking Medicine News(10 mins):